| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Definitive Healthcare Corp. Class A Common Stock$0.74
-0.01 (-1.85%)
Market Cap
135.17 M
EPS
-1.25
P/E Ratio
-0.75 $
Value Trade
284.11 K
SEC Financials
Q1 2026Dilution Risk
Revenue
55.93 M
R&D Expenses
6.50 M
Operating CF
11.56 M
Total Assets
514.74 M
Total Liabilities
324.04 M
Equity
190.70 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
178.09 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
365.45 K
52 Week Range
0.92 - 4.70
% held by Insiders
71.92 %
% held by Institutions
25.42 %
Enterprise Value
224.83 M
Total Shares
105.47 M
Short %
6.85 %
Float Shares
40.82 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Definitive Healthcare Corp. Class A Common Stock (DH) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
DH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
DH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-DH
May 7, 2026Definitive Healthcare Reports Financial Results for First Quarter 2026 First Quarter Revenue at Top End of Guidance Framingham, MA (
Definitive Healthcare Corp. reported its financial results for Q1 2026, showing revenue of $55.9 million, a 6% decrease from Q1 2025. Despite a significant net loss influenced by goodwill impairment charges, the company's adjusted net income rose to $8.5 million from $7.0 million a year prior. CEO Kevin Coop expressed confidence in the company's strategic investments and noted improvements in retention rates. Looking ahead, the guidance for Q2 2026 anticipates revenue between $55.0 and $56.0 million.
Read more →-DH
Feb 26, 2026Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025 Fourth quarter and full year 2025 revenue exceeded guidance Framingham, MA (
Definitive Healthcare Corp. announced its financial results for Q4 and the full fiscal year 2025, reporting a revenue of $61.5 million for the fourth quarter, which marked a 1% decrease from the previous year. However, the company demonstrated significant improvement in net losses compared to Q4 2024, mainly due to a notable reduction in goodwill impairment charges. The overall revenue for the full fiscal year 2025 was reported at $241.5 million, down from $252.2 million in 2024. Despite these challenges, Definitive Healthcare expressed confidence in their strategies for retention and growth as they enter 2026, with optimistic forecasts for revenue and operating income.
Read more →-DH
Nov 6, 2025Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025 Third Quarter Revenue Delivered at High End of Guidance Framingham, MA (
Definitive Healthcare Corp. reported its financial results for the third quarter of fiscal year 2025, revealing revenue of $60.0 million, a 4% decrease from the previous year. However, the company highlighted that its income metrics, including adjusted EBITDA, surpassed expectations, indicating positive operational adjustments. New client acquisitions in the biopharma and medical device sectors contributed to optimistic growth potential. Looking ahead, the company has provided a financial guidance for the fourth quarter, fostering a cautious yet optimistic outlook on revenue.
Read more →-DH
Aug 7, 2025Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025 Second Quarter Revenue Exceeded Guidance Framingham, MA (
Definitive Healthcare reported its financial results for the second quarter of fiscal year 2025, highlighting revenues of $60.8 million, which fell short of last year’s figure but exceeded guidance. The company revealed a net loss reduced sharply from a previous significant loss, signaling operational improvements. Adjusted EBITDA was 31% of revenue, and cash flow from operations reached $9.3 million. Additionally, Definitive Healthcare announced an increase in its revenue guidance and outlook for adjusted EBITDA for the year ahead.
Read more →-DH
May 8, 2025Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025 First Quarter Revenue Exceeded Guidance Framingham, MA (
Definitive Healthcare Corp. reported its financial results for the first quarter of fiscal year 2025, indicating that though revenue exceeded initial guidance, it faced a 7% decline from the previous year. The company registered a significant net loss attributed largely to goodwill impairment charges. However, adjusted income metrics showed a degree of stability, with positive cash flow from operations and strong customer acquisition highlighted as strengths. The firm maintains a focus on operational efficiency and predicts future revenue growth despite ongoing economic uncertainties.
Read more →-DH
Feb 27, 2025Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024 Fourth quarter and full year 2024 revenue exceeded guidance Framingham, MA (
Definitive Healthcare Corp. reported its financial results for the fourth quarter and full fiscal year 2024, where revenue was $62.3 million, a decrease from the previous year. The company experienced a significant net loss of $(591.4) million for the full year, largely due to goodwill impairment charges. However, it achieved an adjusted net income of $55.1 million, and cash flow from operations rose to $58.2 million, reflecting growth. Looking ahead, the company has issued guidance predicting revenue in the range of $230.0 to $240.0 million for 2025.
Read more →-DH
Nov 7, 2024Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024 Third quarter revenue exceeded guidance, and the Company announced a $100 million repurchase authorization Framingham, MA (
Definitive Healthcare reported financial results for the third quarter of fiscal year 2024, surpassing revenue guidance with $62.7 million. The company faced a net loss of $(187.8) million due to goodwill impairment but showed an increase in adjusted net income. Notable elements included the authorization of a $100 million stock repurchase program, growth in enterprise customers, and recent wins with major health organizations. Despite a decline in overall revenue and EBITDA, management expressed optimism about future prospects.
Read more →-DH
Aug 5, 2024Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2024 Second quarter revenue grew 5% year-over-year to $63.7 million Framingham, MA (
Definitive Healthcare reported its financial results for the second quarter of fiscal year 2024, highlighting a 5% increase in revenue year-over-year, totaling $63.7 million. However, the company experienced a significant net loss of $(306.2) million, largely attributed to goodwill impairment charges. Adjusted net income showed some improvement, rising to $14.2 million, while adjusted EBITDA increased by 21% to $20.9 million. Additionally, the enterprise customer base grew 6% from the previous year, ending with 537 enterprise customers.
Read more →-DH
May 7, 2024Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2024 First quarter revenue grew 7% year-over-year to $63.5 million Framingham, MA (
Definitive Healthcare Corp. reported a revenue increase of 7% year-over-year for Q1 2024, totaling $63.5 million. The company also noted improvements in adjusted net income and EBITDA margins, driven by operational efficiencies. Despite these positives, it reported a net loss, although less severe than the prior year. Additionally, the company anticipates modest revenue growth for the upcoming quarter, with a stock repurchase program approved to bolster shareholder value.
Read more →-DH
Feb 28, 2024Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023 Fourth quarter revenue grew 9% year-over-year to $65.9 million Full year 2023 revenue grew 13% year-over-year to $251.4 million
Definitive Healthcare (Nasdaq: DH) reported its financial results for Q4 and the full year 2023, highlighting a 9% increase in quarterly revenue to $65.9 million and a 13% increase in annual revenue to $251.4 million. Despite these positive growth metrics, the company faced a significant net loss of $13.4 million in the fourth quarter and a total annual net loss that rose to $289.6 million. The firm expanded its enterprise client base by 5% during the quarter and plans to continue investments in innovative products for future growth.
Read more →-DH
Jan 16, 2024Definitive Healthcare Announces CEO Transition Jason Krantz, Founder and Executive Chairman, to Serve as Interim CEO Company Reaffirms Fourth Quarter 2023 Guidance and Issues Preliminary Guidance for 2024 Framingham, MA
Definitive Healthcare has announced a leadership transition with Jason Krantz returning as interim CEO following Robert Musslewhite's departure. The company reaffirms its financial guidance for the fourth quarter of 2023 while also providing preliminary guidance for 2024. A global executive search firm has been engaged to find a permanent successor. Krantz aims to foster a smooth transition and maintain momentum during this interim period, highlighting the firm’s positive growth trajectory and commitment to excellence.
Read more →-DH
Jan 4, 2024Team, As we embark upon this new year, I'm writing to share some critical and difficult changes that we are making to our organization to best position us for the future. As we've discussed in Town Halls over the last se
Definitive Healthcare (DH) has announced a significant workforce reduction, laying off 154 employees as part of its ongoing transformation strategy termed 'Go for GOLD.' This decision aims to enhance operational efficiency and free up capital for investment in growth areas. The company acknowledges the emotional toll of these layoffs on the employees and the organization, stating that such difficult choices, while necessary for future restructuring, reflect the company's commitment to revitalizing its operations. The announcement also included details on generous exit packages for departing employees.
Read more →-DH
Nov 2, 2023Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2023 Third quarter revenue grew 14% year-over-year to $65.3 million Framingham, MA (
Definitive Healthcare Corp. reported a 14% increase in revenue for Q3 FY 2023, reaching $65.3 million. The company's adjusted EBITDA also improved to $21.7 million, reflecting better profitability. However, the net loss for the quarter was $248.7 million, which raises concerns despite the positive trends in revenue and client acquisitions. Definitive Healthcare aims to balance growth and profitability while expanding its services in healthcare commercial intelligence.
Read more →-DH
Oct 5, 2023Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer Framingham, MA (
Definitive Healthcare Corp. has appointed Carrie Lazorchak as Chief Revenue Officer, effective November 1, 2023. Lazorchak joins the company from SimilarWeb and has previously worked at Nuance Communications, bringing extensive experience in SaaS sales and customer success. CEO Robert Musslewhite expressed confidence in Lazorchak's fit with the company's culture and her ability to drive growth. Current Chief Revenue Officer Joe Mirisola will transition to a Senior Advisor role before departing at the end of the year.
Read more →-DH
Sep 8, 2023Definitive Healthcare Welcomes Scott Stephenson to Board of Directors Framingham, MA (
Definitive Healthcare Corp. has appointed Scott Stephenson, former CEO of Verisk Analytics, to its Board of Directors, effective September 6, 2023. Stephenson's extensive experience in data analytics is anticipated to significantly contribute to the company's leadership. Concurrently, Chris Mitchell, who played a key role since the company's early days, has stepped down from the Board. This transition comes as Definitive Healthcare aims to expand its innovative SaaS platform and leverage artificial intelligence in the healthcare sector.
Read more →-DH
Aug 14, 2023Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2023 Second quarter revenue grew 12% year-over-year to $61.0 million Framingham, MA (
Definitive Healthcare Corp. reported a 12% revenue increase year-over-year, totaling $61 million for the second quarter of fiscal year 2023. Adjusted Net Income also improved significantly to $12.4 million, showcasing the company's positive trajectory despite a net loss of $11.6 million. Additionally, the company announced the acquisition of Populi, which aims to enhance its analytics and competitive positioning in healthcare commercial intelligence. However, the necessity to restate previous financial reports due to misstatements is a concern.
Read more →-DH
Aug 1, 2023Definitive Healthcare Reports Preliminary Financial Results for Second Quarter Fiscal Year 2023, Reaffirms Full Year Guidance for Revenue and Adjusted EBITDA, and Announces Restatement of Previously Issued Financials Q2
Definitive Healthcare (DH) released preliminary financial results for Q2 2023, reporting expected revenue of $61 million and reaffirming full-year guidance of $249-255 million. However, the company also announced a restatement of previous financials, significantly impacting prior fiscal years, including adjustments related to sales tax accruals. The company anticipates general and administrative expenses will increase by $6.8 million to $10.2 million due to this restatement, and there will be a delay in filing the Q2 2023 10-Q.
Read more →-DH
May 4, 2023Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2023 First quarter revenue grew 18% year-over-year to $59.2 million Framingham, MA (
Definitive Healthcare announced its first-quarter fiscal results for 2023, reporting an 18% rise in revenue to $59.2 million compared to the previous year. Despite a net loss of $15.6 million, the company saw an increase in adjusted net income to $9.2 million. The quarter ended with 529 enterprise clients, and the company highlighted significant client expansions and new product launches. Looking ahead, Definitive Healthcare is optimistic, forecasting continued revenue growth for the second quarter of 2023.
Read more →-DH
Feb 23, 2023Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2022 Fourth quarter revenue grew 31% year-over-year to $60.6 million Full year 2022 revenue grew 34% to $222.7 million Framingham, M
Definitive Healthcare reported strong financial results for Q4 2022 and the full fiscal year, highlighting a 31% increase in quarterly revenue and a notable rise in adjusted net income. Despite a GAAP net loss of $(22.3) million for the year, the company experienced a 34% increase in overall revenue. The launch of the Atlas Dataset is expected to enhance their competitive edge in the healthcare market. The company has provided optimistic financial guidance for 2023, suggesting continued growth prospects.
Read more →-DH
Jan 12, 2023Email to Employees Definitive Healthcare team: Today I m announcing the most difficult decision that we ve ever had to make at Definitive Healthcare. We re reducing the size of our team by around 6% and saying goodbye to
Definitive Healthcare announced a reduction in its workforce by approximately 6%, marking a significant and difficult decision for the company. The executive leadership team attributed the layoffs to a sluggish economy and a need to realign costs with decreasing purchasing decisions. Despite this setback, management remains optimistic about the company's future growth potential, emphasizing their commitment to providing generous severance packages and support for affected employees. The focus now shifts toward supporting departing colleagues while maintaining a path for future business success.
Read more →-DH
Nov 3, 2022Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2022 Third quarter revenue grew 33% year-over-year to $57.4 million Framingham, MA (
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2022 Third quarter revenue grew 33% year-over-year to $57.4 million Framingham, MA (November 3, 2022) Definitive Healthcare Corp. ( Definitive Healthcare or the Company ) (Nasdaq: DH), an industry lea
Read more →-DH
Oct 3, 2022Definitive Healthcare Announces Changes to Board of Directors Sastry Chilukuri joins Board of Directors and Randy Winn departs FRAMINGHAM, MA
Definitive Healthcare Announces Changes to Board of Directors Sastry Chilukuri joins Board of Directors and Randy Winn departs FRAMINGHAM, MA October 3, 2022 Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced two
Read more →-DH
Aug 4, 2022Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2022 Second quarter revenue grew 37% year-over-year to $54.5 million Framingham, MA (
Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2022 Second quarter revenue grew 37% year-over-year to $54.5 million Framingham, MA (August 4, 2022) Definitive Healthcare Corp. ( Definitive Healthcare ) (Nasdaq: DH), an industry leader in healthca
Read more →-DH
May 5, 2022Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2022 First quarter revenue grew 36% year-over-year to $50.1 million Framingham, MA (
Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2022 First quarter revenue grew 36% year-over-year to $50.1 million Framingham, MA (May 5, 2022) Definitive Healthcare Corp. ( Definitive Healthcare ) (Nasdaq: DH), an industry leader in healthcare c
Read more →-DH
Feb 23, 2022Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Year Fiscal 2021 Fourth quarter revenue grew 38% year-over-year to $46.3 million Full year 2021 revenue grew 40% to $166.2 million Framingham, M
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Year Fiscal 2021 Fourth quarter revenue grew 38% year-over-year to $46.3 million Full year 2021 revenue grew 40% to $166.2 million Framingham, MA (February 23, 2022) Definitive Healthcare Corp. ( Defi
Read more →-DH
Nov 8, 2021Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2021 Third quarter revenue grew 43% year-over-year to $43.1 million Framingham, MA (
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2021 Third quarter revenue grew 43% year-over-year to $43.1 million Framingham, MA (November 8, 2021) Definitive Healthcare Corp. ( Definitive Healthcare ) (Nasdaq: DH), an industry leader in healthca
Read more →-DH
Oct 7, 2021Robert Musslewhite Joins Definitive Healthcare as President FRAMINGHAM, MA (
Robert Musslewhite Joins Definitive Healthcare as President FRAMINGHAM, MA (October 7, 2021) Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhite has joined the company as President, a newly create
Read more →-DH
Oct 1, 2021Definitive Healthcare Appoints Kathleen A. Winters to Board of Directors FRAMINGHAM, MA (
Definitive Healthcare Appoints Kathleen A. Winters to Board of Directors FRAMINGHAM, MA (October 1, 2021) Definitive Healthcare (NASDAQ: DH), an industry leader in healthcare commercial intelligence, today announced the appointment of Kathleen A. Winters to its Board of Directo
Read more →-DH
Sep 20, 2021Definitive Healthcare Announces Closing of Public Offering FRAMINGHAM, MA (
Definitive Healthcare Announces Closing of Public Offering FRAMINGHAM, MA (September 20, 2021) Definitive Healthcare Corp. ( Definitive Healthcare ) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the closing of its previously announced i
Read more →Competitive Position
How DH ranks across every disease it competes inCompetitive Position is a premium feature
See how DH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial